Furthermore, HCC patients in the low-risk group exhibited higher IPS in two subtypes [IPS-CTLA4(–)/PD-1(–), IPS-CTLA4(+)/PD-1(–)] and tended to have a better response to ICIs. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.